Browsing Tag
Seagen
7 posts
Insmed (NASDAQ: INSM) rebounds as retail eyes ATS 2026 readouts after Q1 reset
INSM bounced 11% after a 20% post-earnings reset. BRINSUPRI is launching faster than any respiratory drug in a decade. So why did the market sell the print?
Avacta Group (AIM: AVCT) preCISION data signals tumor selectivity index emerging as the new ADC battleground
Avacta is not just challenging Enhertu. It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground.
Can Pfizer’s pipeline offset looming patent cliffs despite a stronger 2025 forecast?
Can Pfizer’s oncology and rare disease pipeline replace billions lost to patent cliffs? Explore how the drugmaker compares with Merck, Bristol Myers, and AstraZeneca.
Pfizer reports strong Q4 2024 earnings, reaffirms 2025 guidance amid cost-cutting strategy
Pfizer Inc. delivered strong fourth-quarter 2024 earnings, exceeding analyst expectations and demonstrating resilience in a challenging pharmaceutical market.…
Pfizer stuns Wall Street with booming Q3 earnings and new guidance boost
Pfizer Inc. delivered a financial jolt in its third quarter of 2024, surpassing Wall Street’s expectations and raising…
Phase 3 EV-302 clinical trial : Seagen, Astellas reveal promising for PADCEV and KEYTRUDA combo
Seagen Inc. and Astellas Pharma Inc. have announced encouraging results from the Phase 3 EV-302 clinical trial, presenting…
Pfizer to acquire cancer-focused drugmaker Seagen in $43bn deal to expand oncology leadership
Pfizer is set to acquire Seagen for $43 billion in cash to boost its oncology drug pipeline and antibody-drug conjugate capabilities. Learn how the deal reshapes cancer therapeutics.